


Improving Pain Management Safety

Title	Improving Pain Management Safety
Description	Percent of households where at least one individual is at risk for adverse opioid event, like overdose or respiratory depression, with naloxone available. A higher score is better
Rationale	Many individuals are at increased risk for adverse events associated with opioid use. Additionally, many states have implemented standing protocols for naloxone dispensing without prescription to patients or caregivers of patients at risk for adverse opioid events. This measure ensures, at a household level, naloxone is available to any patient.
Logic Model	 <p>This measure ensures any household at risk for adverse opioid events is evaluated and provided treatment.</p>
Level of Analysis	Pharmacy (Patient)
Data Source	Pharmacy Data
Denominator Statement	Any household with a patient at risk for adverse opioid event defined as patients prescribed opioids and any of the following: <ul style="list-style-type: none"> • ≥ 50 morphine milligram equivalents per day • Concomitant use of sedating medications, like benzodiazepines
Denominator Calculation	<ol style="list-style-type: none"> 1. All individuals in the pharmacy 2. All individuals prescribed an opioid 3. All individuals with risk factor (≥ 50 MME or benzodiazepine) 4. Exclude non-human patients 5. Identify each unique household
Denominator Exclusions	Any non-human patients (e.g., cats, dogs, clinics, office-use, etc)

Denominator Exclusion Rationale	Pharmacies may provide care to pets or other veterinarian needs, or for office-use. This patient profiles should be excluded from the measure calculation.
Numerator Statement	Household from the denominator with a naloxone dispensed during the measurement year
Numerator Calculation	<ol style="list-style-type: none"> 1. 1. Identify all naloxone prescriptions dispensed from the pharmacy 2. 2. Identify each household with a naloxone prescription 3. 3. Households that have a match in the denominator are in the numerator.
Seguridad Measure Specification Process	<pre> graph TD A[Choose a pharmacy] --> B[Determine the measurement year (typically, previous calendar year)] B --> C[Identify all unique patients that received care in the pharmacy] C --> D[Identify all patients prescribed an opioid] D --> E[Identify all patients prescribed an opioid with at least one risk factor.] E --> F[Exclusions: *Non-human patients] F --> G[This is the denominator] G --> H[Identify all naloxone prescriptions in the pharmacy] H --> I[Identify the unique households that received naloxone] I --> J[Match households with naloxone with any household in the denominator] J --> K[This is the numerator] </pre>
Data Stratification	<p>The measure rate will be reported as a percent of patients within a single pharmacy.</p> <p>If available and feasible, measure rate will be reported by type of pharmacy (e.g., health-system, community, specialty, mail-order, long-term care).</p> <p>If available and feasible, measure rate will be reported by line of business (pharmacy Medicare rate, pharmacy Medicaid rate, pharmacy Commercial rate, and pharmacy uninsured rate).</p> <p>Risk adjustment will be applied when available.</p>
Value Sets	The value set <i>Seguridad – Opioids</i> and <i>Seguridad – Opioid Risk Medications</i> will be used to support the exclusion criteria.
Future Iterations	Many pharmacy measures are designed as structure or process. Future goals of this concept include measures focused on appropriate dosing based on renal function and assessment of all patients.
Harmonization ¹	<p>Payors: PQA’s Opioid Measure Set</p> <p>Providers: PQA’s Opioid Measure Set</p>

1. Measures that have either the same target populations (denominator) or the same measure focus (numerators) may be considered related, whereas measures that have the same targeted population (denominator) and same measure focus (numerator), are considered competing measures. Measures being developed should be harmonized, where feasible, to previously established measures to decrease measure burden. Choose My Pharmacy measures are developed for pharmacy evaluation, which is a novel area for measurement science, no current measure evaluates this level of analysis. Choose My Pharmacy measures will be harmonized to the extent possible, recognizing different levels of analysis have different data elements, and instead the focus will be to vertically integrate the Choose My Pharmacy measures with other measurement systems and measures.

Revision #1

Created 30 August 2023 19:58:15

Updated 30 August 2023 20:03:43